Expansion Therapeutics
Peter Connolly is an accomplished professional in the field of structural biology and biophysics, currently serving as Vice President at Expansion Therapeutics since November 2020, after previously holding positions as Senior Director of Structural Biology and Consultant. Connolly's extensive experience includes over 14 years at Vertex Pharmaceuticals as a Research Fellow, focusing on the structure determination of target proteins using multidimensional heteronuclear NMR and NMR-detected fragment screening. Prior roles at UCB Research and UCB Pharma as Principal Scientist involved similar responsibilities in protein structure determination and fragment library design. Connolly's career began at the Rowland Institute for Science, where contributions included studying protein structure, dynamics, and folding. Peter Connolly holds a Ph.D. in Chemistry from Boston College, earned in 1987.
This person is not in any offices
Expansion Therapeutics
2 followers
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in San Diego, California and Jupiter, Florida.